Welcome to our dedicated page for Clearmind Medicine SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clearmind Medicine's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clearmind Medicine's regulatory disclosures and financial reporting.
Clearmind Medicine Inc. (CMND) furnished a Form 6-K reporting balance-sheet activity and an IP update. The company disclosed that on October 30–31, 2025, an aggregate of $1,045,062 of outstanding amounts due under previously issued convertible promissory notes was converted into 885,000 common shares. This reduces note balances while increasing the equity base.
The filing also attaches a press release announcing the publication of a U.S. patent application for its non-hallucinogenic neuroplastogen MEAI therapy aimed at cocaine addiction. Additionally, the Form 6-K and the first three paragraphs of the press release are incorporated by reference into the company’s effective shelf and equity compensation registration statements (Form F-3 File Nos. 333-275991, 333-270859, 333-273293; Form S-8 File No. 333-283695).
Clearmind Medicine (CMND) furnished a Form 6-K that attaches a press release titled “Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder.” The filing also states that the first four paragraphs of this press release are incorporated by reference into the company’s effective registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), becoming part of those filings to the extent not later superseded.
Clearmind Medicine (CMND) filed a Form 6-K announcing the appointment of Mary-Elizabeth Gifford as Chief of Global Impact to advance US partnerships and governmental engagement. The filing attaches a press release dated October 27, 2025.
The first, second, fifth and sixth paragraphs of that release are incorporated by reference into Clearmind’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695).
Clearmind Medicine Inc. (CMND) furnished a Form 6-K for October 2025, attaching a press release titled “Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder.” The press release is included as Exhibit 99.1.
The filing states that the first three paragraphs of the press release are incorporated by reference into Clearmind’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695) from the date this report is submitted, to the extent not superseded by later filings.
Clearmind Medicine Inc. submitted a Form 6-K for September 2025, mainly to furnish a press release dated September 25, 2025. The release announces the company’s inaugural Scientific Advisory Board meeting, focused on advancing psychedelic-derived therapies, underscoring Clearmind’s emphasis on scientific guidance for its development efforts.
Clearmind Medicine announced a $10.0 million securities purchase agreement intended to explore strategic opportunities. The filing provides the transaction title but no additional terms, counterparties, or timing. The report is signed by CEO Adi Zuloff-Shani, confirming the company disclosed the financing arrangement publicly. With limited detail in this report, the primary fact is the existence of the $10 million agreement to support potential strategic initiatives.
Clearmind Medicine, Inc. submitted a Form 6-K that attaches a Form of Convertible Promissory Note and a Form of Securities Purchase Agreement dated September 17, 2025. The filing states these documents are included as exhibits and will be incorporated into the company’s registration statements (File Nos. 333-275991, 333-270859, 333-273293 and Form S-8 File No. 333-283695) to the extent not superseded by later filings. The report is signed by Adi Zuloff-Shani, Chief Executive Officer, indicating company authorization of the submission.
Clearmind Medicine Inc. submitted a Form 6-K to inform investors that, on September 11, 2025, it filed in Canada its unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis for the three and nine months ended July 31, 2025. These documents were filed with the Canadian Securities Administration and the securities commissions in Ontario, British Columbia and Alberta.
The Form 6-K also states that this report is incorporated by reference into Clearmind’s existing U.S. registration statements on Form F-3 and Form S-8, meaning those offerings now formally include the latest Canadian interim financial statements and MD&A.